Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.630
-0.070 (-4.12%)
At close: Apr 1, 2025, 4:00 PM
1.675
+0.045 (2.73%)
After-hours: Apr 1, 2025, 4:25 PM EDT
Entera Bio Revenue
In the year 2024, Entera Bio had annual revenue of $181.00K. Entera Bio had revenue of $82.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$181.00K
Revenue Growth
n/a
P/S Ratio
339.83
Revenue / Employee
$10,056
Employees
18
Market Cap
60.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 181.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ENTX News
- 4 days ago - Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 15 days ago - OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders - GlobeNewsWire
- 5 weeks ago - Entera Bio to Participate in Upcoming Events - GlobeNewsWire
- 2 months ago - Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 months ago - Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - GlobeNewsWire
- 8 months ago - Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewsWire
- 8 months ago - Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewsWire